Review
Immunology
Seyedeh Zohreh Mirjalili, Reyhaneh Sabourian, Mona Sadeghalvad, Nima Rezaei
Summary: Biosimilars are cost-effective alternatives to reference biological drugs for treating autoimmune disorders. Research indicates that biosimilar mAbs show similarity with reference products in terms of safety and efficacy, making them potential candidates for a wider range of diseases.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Immunology
Susan Pederson, David M. Biondi, Brent Allan, Roger Cady, Barbara Schaeffler, Brian Baker, John Latham
Summary: Across five clinical trials, the immunogenicity of eptinezumab was characterized by low titer and transient ADA and NAb responses, with no clinically meaningful impact on efficacy and safety profiles. The onset of detectable ADA occurred at week 8, peaked at week 24, and declined steadily thereafter, regardless of eptinezumab dose level or number of doses.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Engineering, Multidisciplinary
Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen
Summary: The modification of therapeutic antibodies is booming in research and development to improve efficacy. China, as an active player in the biopharmaceutical field, shows a great demand and potential in this area.
Article
Chemistry, Multidisciplinary
Rinie Bajracharya, Esteban Cruz, Jurgen Gotz, Rebecca M. Nisbet
Summary: Tau-specific immunotherapy is a promising treatment strategy for Alzheimer's disease. However, the blood-brain barrier poses a challenge for effective delivery of tau-specific antibodies. Previous research has shown that low-intensity scanning ultrasound combined with microbubbles can increase antibody passage into the brain. This study aimed to assess the therapeutic response of ultrasound-mediated delivery of tau-specific antibodies.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Pharmacology & Pharmacy
Yu Cong, Eric M. Mucker, Donna L. Perry, Saurabh Dixit, Erin Kollins, Russ Byrum, Louis Huzella, Robert Kim, Mathew Josleyn, Steven Kwilas, Christopher Stefan, Charles J. Shoemaker, Jeff Koehler, Susan Coyne, Korey Delp, Janie Liang, David Drawbaugh, Amanda Hischak, Randy Hart, Elena Postnikova, Nick Vaughan, Jason Asher, Marisa St Claire, Jarod Hanson, Connie Schmaljohn, Ann E. Eakin, Jay W. Hooper, Michael R. Holbrook
Summary: The rapid development of therapeutic antibody treatments for COVID-19 was investigated in this research. Sixteen candidate antibody products were evaluated for their activity against SARS-CoV-2 and tested in a Syrian hamster model. The efficacy of therapeutic antibodies in treating viral infection was confirmed, providing valuable data for clinical drug development.
ANTIVIRAL RESEARCH
(2023)
Article
Medicine, General & Internal
Rachel A. Bender Ignacio, Kara W. Chew, Carlee Moser, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan, Mark J. Giganti, Evgenia Aga, Michael Gibbs, Herve Tchouakam Kouekam, Eva Johnsson, Mark T. Esser, Keila Hoover, Gene Neytman, Matthew Newell, Eric S. Daar, William Fischer, Courtney V. Fletcher, Jonathan Z. Li, Alexander L. Greninger, Robert W. Coombs, Michael D. Hughes, Davey Smith, David Alain Wohl
Summary: These two clinical trials showed that tixagevimab and cilgavimab monoclonal antibodies were safe and effective for treating early COVID-19, but did not change the time to symptom improvement. The treatment outcomes were better for the intramuscular injection.
Article
Chemistry, Analytical
Beijun Ang, Xinxin Xu, Liguang Xu, Liqiang Liu, Hua Kuang, Chuanlai Xu
Summary: In this study, a method combining enzymatic hydrolysis with a colloidal gold lateral flow immunoassay (LFIA) was established to detect total homocysteine (tHcy) in blood, which has the potential to predict cardiovascular risk accurately.
Article
Multidisciplinary Sciences
Kazuto Nakae, Sho Masui, Atsushi Yonezawa, Motomu Hashimoto, Ryu Watanabe, Koichi Murata, Kosaku Murakami, Masao Tanaka, Hiromu Ito, Kotoko Yokoyama, Noriko Iwamoto, Takashi Shimada, Miyuki Nakamura, Masaya Denda, Kotaro Itohara, Shunsaku Nakagawa, Yasuaki Ikemi, Satoshi Imai, Takayuki Nakagawa, Makoto Hayakari, Kazuo Matsubara
Summary: Infliximab therapy has significantly improved the treatment of rheumatoid arthritis. Monitoring serum IFX levels can help identify secondary non-responders and optimize treatment in clinical practice by avoiding primary ineffectiveness with appropriate dose escalation.
Article
Immunology
Long Liu, Lu Qi, Chunpu Lei, Yu Wang, Wei Zhang, Ying Liu, Pu Li, Haihong Bai, Yan Li, Yinjuan Li, Ju Liu, Liangzhi Xie, Xinghe Wang
Summary: This study compared the pharmacokinetics, safety, and immunogenicity of the adalimumab biosimilar SCT630 with its reference drug. The results showed that SCT630 was bioequivalent to adalimumab in terms of pharmacokinetic parameters, and had similar safety and immunogenicity profiles.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Immunology
Chang Liu, Wenliang Dong, Lin Xia, Jie Lv, Daoli Jiang, Qian Wang, Mei Wang, Maofeng Wu, Jingwei Miao, Tao Tao, Dong Wang, Lili Zheng, Shiguang Su, Lizhong Liu, Yi Fang
Summary: The study aimed to evaluate the safety, tolerability, and immunogenicity of SSS07 in healthy volunteers. Results showed higher immunogenicity at low doses of SSS07, but overall, the treatment was safe and well tolerated in healthy Chinese volunteers.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Microbiology
Matthew Slarve, Zeferino Reyna, Elizabeth Burk, Juan Ruiz-Delgado, Rachel Li, Jun Yan, Brian Luna, Brad Spellberg
Summary: Researchers have identified the antibody MAb5, which demonstrates broad binding against both U.S. and international isolates of A. baumannii and shows protective efficacy in vivo.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Multidisciplinary Sciences
Simone Lanini, Stefano Milleri, Emanuele Andreano, Sarah Nosari, Ida Paciello, Giulia Piccini, Alessandra Gentili, Adhuna Phogat, Inesa Hyseni, Margherita Leonardi, Alessandro Torelli, Emanuele Montomoli, Andrea Paolini, Andrea Frosini, Andrea Antinori, Emanuele Nicastri, Enrico Girardi, Maria Maddalena Plazzi, Giuseppe Ippolito, Francesco Vaia, Giovanni Della Cioppa, Rino Rappuoli
Summary: The emergence of SARS-CoV-2 variants poses a new threat to the clinical management of COVID-19. MAD0004J08 is a potent monoclonal antibody that can neutralize all variants, including the omicron variant, with reduced potency. In a phase 1 clinical study, a single dose of MAD0004J08 was found to be safe, well-tolerated, and effective in neutralizing major variants.
NATURE COMMUNICATIONS
(2022)
Article
Pharmacology & Pharmacy
Xiaoxiao Huang, Xiaobin Xu, Michael A. Partridge, Jihua Chen, Ellen Koehler-Stec, Giane Sumner, Haibo Qiu, Albert Torri, Ning Li
Summary: An urgent need exists for new technologies to characterize immunogenicity to biotherapeutics. In this study, an immunocapture LC-MS assay was developed to determine monkey anti-drug antibody isotypes and semi-quantify them. Results showed that IgG1 was the most abundant isotype in ADA-positive samples, and the LC-MS ADA assay provided additional isotype information compared to traditional ligand binding assays.
Review
Virology
Leonardo F. Ormundo, Carolina T. Barreto, Lilian R. Tsuruta
Summary: Antibody-based passive immunotherapy is effective in treating and preventing infectious diseases. Selecting neutralizing monoclonal antibodies (mAbs) and developing highly effective mAbs have become important strategies in combating emerging arbovirus infections.
Article
Immunology
Michael D. Swanson, Shantel Rios, Sarita Mittal, George Soder, Vibha Jawa
Summary: Aggregates of therapeutic proteins have been found to increase immunogenicity risks, with spontaneously occurring aggregates able to induce innate immune responses. The impact of different aggregate samples on immune responses may vary.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Chemistry, Medicinal
Ji-Sun Kim, Sei-Yong Jun, Yong-Sung Kim
JOURNAL OF PHARMACEUTICAL SCIENCES
(2020)
Article
Multidisciplinary Sciences
Seung-Min Shin, Ji-Sun Kim, Seong-Wook Park, Sei-Yong Jun, Hye-Jin Kweon, Dong-Ki Choi, Dakeun Lee, Yong Beom Cho, Yong-Sung Kim
Article
Biochemistry & Molecular Biology
Jong-Hee Ko, Hyuk-Sang Kwon, Bomin Kim, Gihong Min, Chorong Shin, Seok-Woo Yang, Seong Wook Lee, Youngmin Lee, Dahae Hong, Yong-Sung Kim
Article
Immunology
Jung-Eun Kim, Dong-Hyun Lee, Keunok Jung, Eun-Ji Kim, Youngwoo Choi, Hae-Sim Park, Yong-Sung Kim
Summary: Patients with severe eosinophilic asthma often experience frequent exacerbations, but targeting IL-5 and IL-5 receptor alpha with antibodies has shown promise in controlling eosinophilia. A new humanized anti-IL-5R alpha Ab, with stronger affinity and potent biological activity compared to a clinically relevant benralizumab analogue, has been developed as a potential alternative therapy for SEA.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Se-Young Lee, Deok-Han Ko, Min-Jeong Son, Jeong-Ah Kim, Keunok Jung, Yong-Sung Kim
Summary: A TCR-like antibody specific for CMV infection was engineered with increased affinity, which can be used for detection and treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Ji Eun Lee, Yeo Wool Kang, Kyung Hee Jung, Mi Kwon Son, Seung-Min Shin, Ji-Sun Kim, Soo Jung Kim, Zhenghuan Fang, Hong Hua Yan, Jung Hee Park, Young-Chan Yoon, Boreum Han, Min Ji Cheon, Min Gyu Woo, Myung Sung Seo, Joo Han Lim, Yong-Sung Kim, Soon-Sun Hong
Summary: A developed antibody RT22-ep59 targets mutant KRAS and shows synergistic inhibitory effects with gemcitabine on pancreatic cancer cells, suggesting a potential therapeutic strategy for patients with KRAS mutation.
Article
Biochemistry & Molecular Biology
Seong-Wook Park, Sei-Yong Jun, Ji-Sun Kim, Yong-Sung Kim
Summary: By engineering a higher affinity EpCAM-targeting cyclic peptide, the peptide-fused antibody showed enhanced cellular internalization and tumor accumulation, leading to more efficient antitumor effects.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Ji Eun Lee, Min Gyu Woo, Kyung Hee Jung, Yeo Wool Kang, Seung-Min Shin, Mi Kwon Son, Zhenghuan Fang, Hong Hua Yan, Jung Hee Park, Young-Chan Yoon, Yong-Sung Kim, Soon-Sun Hong
Summary: KRAS activating mutations are common in pancreatic cancer and drive tumor dependency on the RAS/MAPK and PI3K/AKT signaling pathways. This study found that targeting both pathways may be necessary for optimal therapeutic effect. The developed inRas37 antibody significantly increased the drug response of the PI3K inhibitor BEZ-235 by inhibiting MAPK reactivation. The combination treatment showed synergistic activity in inhibiting cell proliferation, migration, and invasion, and effectively inhibited tumor growth in mouse models.
BIOMOLECULES & THERAPEUTICS
(2022)
Article
Immunology
Sua Lee, Shina Jang, Jihoon Kang, Soo Bin Park, Young Woo Han, Hyemi Nam, Munkyung Kim, Jeewon Lee, Ki Joon Cho, Jeonghun Kim, Miyoung Oh, Jihye Ryu, Jong Hyeon Seok, Yunhwa Kim, Jee-Boong Lee, Man-Seong Park, Yong-Sung Kim, Hosun Park, Dong-Sik Kim
Summary: A universal SARS-CoV-2 neutralizing antibody, MG1141A, was developed in this study, which effectively neutralizes live viruses and retains its activity against various variants of SARS-CoV-2, contributing to the development of a novel antibody therapeutic approach.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Keunok Jung, Min-Jeong Son, Se-Young Lee, Jeong-Ah Kim, Deok-Han Ko, Sojung Yoo, Chul-Ho Kim, Yong-Sung Kim
Summary: A new antibody technology has been developed to deliver viral epitopes into tumor cells, aiding immune cells to more effectively attack tumor cells.
Article
Biochemistry & Molecular Biology
Seong-Wook Park, Da-Som Lee, Yong-Sung Kim
Summary: Ub ligases play a crucial role in protein degradation by attaching ubiquitin (Ub) to substrate proteins. In this study, the U-box domain of human U-box-type E3 E4B (E4BU) was engineered to enhance its Ub ligase function. A functional screening system identified an improved E4BU variant, E4BU(#8), with a higher Ub ligase activity rate. E4BU(#8) showed retained substrate degradation activity essential for targeted protein degradation. This engineered E4BU(#8) may have potential as a valuable tool in designing biological molecules for protein degradation.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Immunology
Keunok Jung, Sojung Yoo, Jung-Eun Kim, Wook Kim, Yong-Sung Kim
Summary: Tumor-targeting antibody-fused cytokines can enhance antitumor efficacy and reduce toxicity by delivering cytokines to tumors. However, the localization and penetration of these immunocytokines within solid tumors pose challenges. This study found that optimizing the tumor antigen-binding kinetics and affinity of the antibody moiety is crucial for achieving maximal antitumor efficacy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Sei-Yong Jun, Dae-Seong Kim, Yong-Sung Kim
Summary: Based on an anti-EGFR monobody, this study developed a new strategy for immunotoxins that can distinguish between cells with EGFR overexpression in tumors and normal tissues, providing a new approach for targeting antigens overexpressed in tumors in broad normal tissues with immunotoxins.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Immunology
Jun-Ho Kim, Dae-Seong Kim, Hae-Sim Park, Yong-Sung Kim
Summary: This study proposes a new treatment approach for severe eosinophilic asthma by eliminating eosinophils using engineered T cells. By designing different formats of bispecific T-cell engagers, the researchers identified a format with the highest affinity for eosinophils and demonstrated its cytotoxicity against these cells using T cells from healthy donors. Importantly, this study shows the potential of bispecific T-cell engagers as an alternative treatment for eosinophilic asthma and expands their application beyond cancer cells.
CLINICAL IMMUNOLOGY
(2023)
Letter
Oncology
Keunok Jung, Deok-Han Ko, Jeong-Yun Jang, Young Rong Kim, Jung Yeon Heo, Yong-Sung Kim
CANCER COMMUNICATIONS
(2023)